The Current Ulcerative Colitis (UC) Treatment Algorithm: From 5-ASA to Biological Therapies
DOI:
https://doi.org/10.12775/QS.2025.47.66966Keywords
ulcerative colitis, 5-ASA, monoclonal antibodies, JAK kinases, ulcerative colitis treatment, inflammatory bowel diseaseAbstract
Background: Ulcerative colitis (UC) is a chronic, relapsing inflammatory condition affecting the colonic mucosa, typically progressing proximally from the rectum. Incidence rates are rising globally. The etiology is multifactorial, involving genetic susceptibility and environmental triggers such as smoking status and diet.
Aim: The aim of this article is to provide a comprehensive review of the current therapeutic landscape for ulcerative colitis, evaluating the efficacy and safety of established and novel pharmacological agents based on a systematic review of clinical trials and meta-analyses.
Materials and Methods: The review included scientific papers sourced from the PubMed and Google Scholar databases.
Results: Treatment strategies vary by disease severity. 5-aminosalicylates (5-ASA) remain the first-line therapy for inducing and maintaining remission in mild-to-moderate UC. For moderate-to-severe disease, corticosteroids are effective for induction but limited by systemic toxicity, leading to the development of second-generation formulations like Budesonide MMX. In steroid-refractory or dependent cases, biological therapies—including anti-TNF agents (infliximab, adalimumab), anti-integrins (vedolizumab), and interleukin inhibitors (ustekinumab) demonstrate significant efficacy. Recently, oral small molecules such as JAK inhibitors (tofacitinib, upadacitinib) and S1P receptor modulators (ozanimod) have emerged as potent, non-immunogenic alternatives.
Conclusions: The management of UC has evolved from symptom control to achieving deep endoscopic remission and improving health-related quality of life. While conventional therapies remain foundational, the expansion of biologics and small molecules offers critical options for refractory patients, helping to reduce colectomy rates. Optimal treatment requires balancing therapeutic efficacy with long-term safety profiles.
References
Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., Fiorino, G., Gearry, R., Krishnareddy, S., Lakatos, P. L., Loftus, E. V., Jr, Marteau, P., Munkholm, P., Murdoch, T. B., Ordás, I., Panaccione, R., … Colombel, J. F. (2015). Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. The American journal of gastroenterology, 110(9), 1324–1338. https://doi.org/10.1038/ajg.2015.233
Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L., & Colombel, J. F. (2017). Ulcerative colitis. Lancet (London, England), 389(10080), 1756–1770. https://doi.org/10.1016/S0140-6736(16)32126-2
Ananthakrishnan A. N. (2015). Epidemiology and risk factors for IBD. Nature reviews. Gastroenterology & hepatology, 12(4), 205–217. https://doi.org/10.1038/nrgastro.2015.34
Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Schumm, L. P., Sharma, Y., Anderson, C. A., Essers, J., Mitrovic, M., Ning, K., Cleynen, I., Theatre, E., Spain, S. L., Raychaudhuri, S., Goyette, P., Wei, Z., Abraham, C., … Cho, J. H. (2012). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491(7422), 119–124. https://doi.org/10.1038/nature11582
Mahid, S. S., Minor, K. S., Soto, R. E., Hornung, C. A., & Galandiuk, S. (2006). Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clinic proceedings, 81(11), 1462–1471. https://doi.org/10.4065/81.11.1462
Odes, H. S., Fich, A., Reif, S., Halak, A., Lavy, A., Keter, D., Eliakim, R., Paz, J., Broide, E., Niv, Y., Ron, Y., Villa, Y., Arber, N., & Gilat, T. (2001). Effects of current cigarette smoking on clinical course of Crohn's disease and ulcerative colitis. Digestive diseases and sciences, 46(8), 1717–1721. https://doi.org/10.1023/a:1010609722315
Andersson, R. E., Olaison, G., Tysk, C., & Ekbom, A. (2001). Appendectomy and protection against ulcerative colitis. The New England journal of medicine, 344(11), 808–814. https://doi.org/10.1056/NEJM200103153441104
Singh, N., & Bernstein, C. N. (2022). Environmental risk factors for inflammatory bowel disease. United European gastroenterology journal, 10(10), 1047–1053. https://doi.org/10.1002/ueg2.12319
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., Barrett, K. J., Davies, R. J., Bennett, C., Gittens, S., Dunlop, M. G., Faiz, O., Fraser, A., Garrick, V., Johnston, P. D., Parkes, M., … Hawthorne, A. B. (2019). British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 68(Suppl 3), s1–s106. https://doi.org/10.1136/gutjnl-2019-318484
Dull, B. J., Salata, K., Van Langenhove, A., & Goldman, P. (1987). 5-Aminosalicylate: oxidation by activated leukocytes and protection of cultured cells from oxidative damage. Biochemical pharmacology, 36(15), 2467–2472. https://doi.org/10.1016/0006-2952(87)90518-1
Stenson W. F. (1990). Role of eicosanoids as mediators of inflammation in inflammatory bowel disease. Scandinavian journal of gastroenterology. Supplement, 172, 13–18. https://doi.org/10.3109/00365529009091903
MacDermott, R. P., Schloemann, S. R., Bertovich, M. J., Nash, G. S., Peters, M., & Stenson, W. F. (1989). Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology, 96(2 Pt 1), 442–448. https://doi.org/10.1016/0016-5085(89)91569-2
Bressler, B., Marshall, J. K., Bernstein, C. N., Bitton, A., Jones, J., Leontiadis, G. I., Panaccione, R., Steinhart, A. H., Tse, F., Feagan, B., & Toronto Ulcerative Colitis Consensus Group (2015). Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology, 148(5), 1035–1058.e3. https://doi.org/10.1053/j.gastro.2015.03.001
Feagan, B. G., Chande, N., & MacDonald, J. K. (2013). Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews. Inflammatory bowel diseases, 19(9), 2031–2040. https://doi.org/10.1097/MIB.0b013e3182920108
Pruitt, R., Hanson, J., Safdi, M., Wruble, L., Hardi, R., Johanson, J., Koval, G., Riff, D., Winston, B., Cross, A., Doty, P., & Johnson, L. K. (2002). Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. The American journal of gastroenterology, 97(12), 3078–3086. https://doi.org/10.1111/j.1572-0241.2002.07103.x
Dubois-Camacho, K., Ottum, P. A., Franco-Muñoz, D., De la Fuente, M., Torres-Riquelme, A., Díaz-Jiménez, D., Olivares-Morales, M., Astudillo, G., Quera, R., & Hermoso, M. A. (2017). Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. World journal of gastroenterology, 23(36), 6628–6638. https://doi.org/10.3748/wjg.v23.i36.6628
Ford, A. C., Bernstein, C. N., Khan, K. J., Abreu, M. T., Marshall, J. K., Talley, N. J., & Moayyedi, P. (2011). Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. The American journal of gastroenterology, 106(4), 590–600. https://doi.org/10.1038/ajg.2011.70
Sandborn, W. J., Danese, S., D'Haens, G., Moro, L., Jones, R., Bagin, R., Huang, M., David Ballard, E., Masure, J., & Travis, S. (2015). Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Alimentary pharmacology & therapeutics, 41(5), 409–418. https://doi.org/10.1111/apt.13076
Mulder, C. J., Fockens, P., Meijer, J. W., van der Heide, H., Wiltink, E. H., & Tytgat, G. N. (1996). Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. European journal of gastroenterology & hepatology, 8(6), 549–553. https://doi.org/10.1097/00042737-199606000-00010
Järnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlén, P., Grännö, C., Vilien, M., Ström, M., Danielsson, A., Verbaan, H., Hellström, P. M., Magnuson, A., & Curman, B. (2005). Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology, 128(7), 1805–1811. https://doi.org/10.1053/j.gastro.2005.03.003
Reinisch, W., Sandborn, W. J., Hommes, D. W., D'Haens, G., Hanauer, S., Schreiber, S., Panaccione, R., Fedorak, R. N., Tighe, M. B., Huang, B., Kampman, W., Lazar, A., & Thakkar, R. (2011). Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut, 60(6), 780–787. https://doi.org/10.1136/gut.2010.221127
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., de Villiers, W. J., Present, D., Sands, B. E., & Colombel, J. F. (2005). Infliximab for induction and maintenance therapy for ulcerative colitis. The New England journal of medicine, 353(23), 2462–2476. https://doi.org/10.1056/NEJMoa050516
Sandborn, W. J., Feagan, B. G., Marano, C., Zhang, H., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Colombel, J. F., Reinisch, W., Gibson, P. R., Collins, J., Järnerot, G., Hibi, T., Rutgeerts, P., & PURSUIT-SC Study Group (2014). Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology, 146(1), 85–e15. https://doi.org/10.1053/j.gastro.2013.05.048
Colombel, J. F., Sands, B. E., Rutgeerts, P., Sandborn, W., Danese, S., D'Haens, G., Panaccione, R., Loftus, E. V., Jr, Sankoh, S., Fox, I., Parikh, A., Milch, C., Abhyankar, B., & Feagan, B. G. (2017). The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut, 66(5), 839–851. https://doi.org/10.1136/gutjnl-2015-311079
Sands, B. E., Sandborn, W. J., Panaccione, R., O'Brien, C. D., Zhang, H., Johanns, J., Adedokun, O. J., Li, K., Peyrin-Biroulet, L., Van Assche, G., Danese, S., Targan, S., Abreu, M. T., Hisamatsu, T., Szapary, P., Marano, C., & UNIFI Study Group (2019). Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. The New England journal of medicine, 381(13), 1201–1214. https://doi.org/10.1056/NEJMoa1900750
Agashe, R. P., Lippman, S. M., & Kurzrock, R. (2022). JAK: Not Just Another Kinase. Molecular cancer therapeutics, 21(12), 1757–1764. https://doi.org/10.1158/1535-7163.MCT-22-0323
Sandborn, W. J., Su, C., Sands, B. E., D'Haens, G. R., Vermeire, S., Schreiber, S., Danese, S., Feagan, B. G., Reinisch, W., Niezychowski, W., Friedman, G., Lawendy, N., Yu, D., Woodworth, D., Mukherjee, A., Zhang, H., Healey, P., Panés, J., & OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators (2017). Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. The New England journal of medicine, 376(18), 1723–1736. https://doi.org/10.1056/NEJMoa1606910
Friedberg, S., Choi, D., Hunold, T., Choi, N. K., Garcia, N. M., Picker, E. A., Cohen, N. A., Cohen, R. D., Dalal, S. R., Pekow, J., Sakuraba, A., Krugliak Cleveland, N., & Rubin, D. T. (2023). Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 21(7), 1913–1923.e2. https://doi.org/10.1016/j.cgh.2023.03.001
Sandborn, W. J., Feagan, B. G., D'Haens, G., Wolf, D. C., Jovanovic, I., Hanauer, S. B., Ghosh, S., Petersen, A., Hua, S. Y., Lee, J. H., Charles, L., Chitkara, D., Usiskin, K., Colombel, J. F., Laine, L., Danese, S., & True North Study Group (2021). Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. The New England journal of medicine, 385(14), 1280–1291. https://doi.org/10.1056/NEJMoa2033617
Sandborn, W. J., Vermeire, S., Peyrin-Biroulet, L., Dubinsky, M. C., Panes, J., Yarur, A., Ritter, T., Baert, F., Schreiber, S., Sloan, S., Cataldi, F., Shan, K., Rabbat, C. J., Chiorean, M., Wolf, D. C., Sands, B. E., D'Haens, G., Danese, S., Goetsch, M., & Feagan, B. G. (2023). Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet (London, England), 401(10383), 1159–1171. https://doi.org/10.1016/S0140-6736(23)00061-2
Armuzzi, A., & Liguori, G. (2021). Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 53(7), 803–808. https://doi.org/10.1016/j.dld.2021.03.002
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Emilia Szczerek, Viktoria Płóciniczak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 36
Number of citations: 0
